Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Embecta (NASDAQ:EMBC) is the #1 top healthcare stock out of 1099 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: D, Financials: A, and AI: C.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock return 7.3% over the past year, overperforming other healthcare stocks by 33 percentage points.

Embecta has an average 1 year price target of $18.50, an upside of 38.27% from Embecta's current stock price of $13.38.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #2 top healthcare stock out of 1099 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 37, which is 12 points higher than the healthcare sector average of 25. It passed 12 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 17.85% over the past year, overperforming other healthcare stocks by 43 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $14.00, an upside of 40.42% from Amneal Pharmaceuticals's current stock price of $9.97.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top healthcare stock out of 1099 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: B.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 47, which is 22 points higher than the healthcare sector average of 25. It passed 15 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 61.46% over the past year, overperforming other healthcare stocks by 87 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $13.00, an upside of 15.35% from Aurinia Pharmaceuticals's current stock price of $11.27.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Aurinia Pharmaceuticals, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 70 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 13.81%, which is 12 percentage points higher than the healthcare sector average of 2.11%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 35.1% indicates that its high dividend yield is sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 9.46%, which is 7 percentage points higher than the healthcare sector average of 2.11%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 8%, which is 6 percentage points higher than the healthcare sector average of 2.11%. Spok Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 150.6% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -2.14% in the last day, and down -1.26% over the last week. Xenetic Biosciences was the among the top losers in the healthcare sector, dropping -33.09% yesterday.

Xenetic Biosciences shares are trading lower after the company announced the pricing of a $4.5 million offering of 735,000 shares at $6.12 per share.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -23.76% in the past year. It has overperformed other stocks in the healthcare sector by 2 percentage points.

Embecta (NASDAQ:EMBC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has gained 7.3% in the past year. It has overperformed other stocks in the healthcare sector by 33 percentage points.

Auna Sa (NYSE:AUNA) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Auna Sa has a valuation score of 29, which is 13 points higher than the healthcare sector average of 16. It passed 2 out of 7 valuation due diligence checks.

Auna Sa's stock has dropped -5.48% in the past year. It has overperformed other stocks in the healthcare sector by 20 percentage points.

52.9% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 34.8% over the next year.

5.15% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.4% of healthcare stocks are rated B (Buy), 48.42% are rated C (Hold), 23.98% are rated D (Sell), and 10.06% are rated F (Strong Sell).